| 28/05/26 | 14:00:00 | 28 May 2026 | | Result of AGM |
| 21/05/26 | 13:00:00 | 21 May 2026 | | Grant of options and PDMR dealing |
| 18/05/26 | 07:00:10 | 18 May 2026 | | Upcoming conference attendance |
| 28/04/26 | 16:28:19 | 28 Apr 2026 | | Posting of Annual Report and Notice of AGMm |
| 13/04/26 | 07:00:06 | 13 Apr 2026 | | Final Results |
| 30/03/26 | 07:00:12 | 30 Mar 2026 | | Notice of FY25 Results |
| 26/03/26 | 07:00:10 | 26 Mar 2026 | | Ligand Pharmaceuticals Milestone Payment |
| 09/03/26 | 07:00:14 | 9 Mar 2026 | | Arecor to present at Oppenheimer conference |
| 09/02/26 | 07:00:10 | 9 Feb 2026 | | 2025 Business Update |
| 06/01/26 | 14:01:10 | 6 Jan 2026 | | Fireside Panel Discussion on Diabetes sector |
| 09/12/25 | 07:00:10 | 9 Dec 2025 | | Arecor and Sequel Med Tech to host fireside panel |
| 17/11/25 | 11:37:04 | 17 Nov 2025 | | Holding(s) in Company |
| 11/11/25 | 09:50:26 | 11 Nov 2025 | | Holding(s) in Company |
| 04/11/25 | 07:00:13 | 4 Nov 2025 | | Enhanced IP Coverage: AT278 & Oral Peptide Program |
| 29/09/25 | 07:00:18 | 29 Sept 2025 | | Directorate Changes |
| 25/09/25 | 07:00:13 | 25 Sept 2025 | | Interim results for the six months to 30 June 2025 |
| 25/09/25 | 07:00:08 | 25 Sept 2025 | | Co-Development Agreement & Monetisation Deal |
| 24/09/25 | 09:30:01 | 24 Sept 2025 | | Notice of Interim Results |
| 04/09/25 | 07:00:03 | 4 Sept 2025 | | Positive FDA Feedback on Phase 2 Study Design |
| 28/08/25 | 12:00:01 | 28 Aug 2025 | | Holding(s) in Company |
| 08/08/25 | 07:00:12 | 8 Aug 2025 | | Change of Auditor |
| 14/07/25 | 07:00:14 | 14 Jul 2025 | | Arecor Establishes New Scientific Advisory Board |
| 04/06/25 | 07:00:10 | 4 Jun 2025 | | Grant of Options and PDMR Dealing |
| 02/06/25 | 13:32:27 | 2 Jun 2025 | | Result of AGM |
| 02/06/25 | 07:00:14 | 2 Jun 2025 | | Non-Executive Director Board Change |
| 21/05/25 | 07:00:10 | 21 May 2025 | | Director/PDMR Dealing |
| 19/05/25 | 07:00:02 | 19 May 2025 | | Arecor Partnership with Skye Bioscience |
| 14/05/25 | 14:37:21 | 14 May 2025 | | Director Dealing |
| 08/05/25 | 07:00:08 | 8 May 2025 | | Arecor sells rights to non-Ogluo® products |
| 06/05/25 | 16:42:37 | 6 May 2025 | | Posting of 2024 Annual Report and Notice of AGM |
| 24/04/25 | 07:00:13 | 24 Apr 2025 | | Arecor to present on Investor Meet Company |
| 23/04/25 | 07:00:08 | 23 Apr 2025 | | Grant of Options and PDMR Dealing |
| 22/04/25 | 07:00:13 | 22 Apr 2025 | | Final results for 2024 |
| 10/04/25 | 07:00:13 | 10 Apr 2025 | | Notice of Results |
| 26/03/25 | 07:00:09 | 26 Mar 2025 | | Collaboration with global pharmaceutical partner |
| 12/03/25 | 07:00:04 | 12 Mar 2025 | | Arecor partnership with biopharmaceutical company |
| 03/02/25 | 07:00:07 | 3 Feb 2025 | | Arecor Full Year 2024 Trading Update |
| 10/01/25 | 07:45:00 | 10 Jan 2025 | | Orderly Cessation of Tetris Pharma Operations |
| 09/01/25 | 07:00:06 | 9 Jan 2025 | | Change of Nominated Advisor and Joint Broker |
| 30/12/24 | 07:00:03 | 30 Dec 2024 | | Arecor Signs Exclusive Licensing Agreement |
| 02/12/24 | 07:00:07 | 2 Dec 2024 | | Grant of Options and PDMR Dealing |
| 18/11/24 | 07:00:06 | 18 Nov 2024 | | Arecor Appoints Interim Chief Financial Officer |
| 27/09/24 | 07:00:10 | 27 Sept 2024 | | Arecor to present on Investor Meet Company |
| 26/09/24 | 07:00:12 | 26 Sept 2024 | | Interim Results for six months ended 30 June 2024 |
| 19/09/24 | 15:17:06 | 19 Sept 2024 | | Notice of Results |
| 11/09/24 | 07:00:08 | 11 Sept 2024 | | Arecor presents positive AT278 data at EASD |
| 03/09/24 | 07:00:12 | 3 Sept 2024 | | Arecor announces AT278 presentation at EASD 2024 |
| 22/08/24 | 16:34:01 | 22 Aug 2024 | | Holding(s) in Company |
| 20/08/24 | 13:44:11 | 20 Aug 2024 | | Holding(s) in Company |
| 12/08/24 | 15:02:46 | 12 Aug 2024 | | Holding(s) in Company |
